Better Buy Now: Novo Nordisk vs. Eli Lilly
November isn't half-finished, and it's already shaping up to be an exciting month for pharmaceutical companies that market weight-management drugs. On Nov. 8, the active ingredient in Eli Lilly's (NYSE: LLY) type 2 diabetes treatment Mounjaro earned approval from the Food and Drug Administration (FDA) for chronic weight management under a new brand name, Zepbound.
Just a few days later, Novo Nordisk (NYSE: NVO) released positive results from a closely watched clinical trial with its weight-management drug Wegovy.
Image source: Getty Images.
Source Fool.com
